Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide
- Registration Number
- NCT00463983
- Lead Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Brief Summary
Octreotide is a somatostatin analog with a long half-life in vivo. Octreotide has interesting anti-inflammatory and anti-fibrotic properties in vitro and in vivo. Somatostatin receptors are increased and Octreotide uptake is increased in the lung in patients with idiopathic pulmonary fibrosis. Our hypothesis is that octreotide may slow the degradation of lung function in patients with IPF. In this proof of concept study, patients with IPF will receive an intramuscular injection of slow release octreotide (Sandostatin LP, 30 mg)every 4 weeks for 48 weeks. Lung function (FVC, DLCO), HRCT scores for fibrosis and ground glass, 6 minute walking test,quality of life and survival will be monitored.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
- confident diagnosis of IPF according to ATS/ERS criteria
Read More
Exclusion Criteria
- known intolerance to somatostatin or octreotide
- another disease with predicted survival < 12 months
- pregnancy or lactation
- previous treatment with somatostatin or somatostatin analogs
- patient on a waiting list for transplantation
- antifibrotic treatment or prednisone > 10 mg/day within the last 6 weeks
- symptomatic biliary lithiasis
- blood coagulation disorders that prevent intra-muscular injections
- HIV infection
- hepatitis B or C active infection
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description octreotide octreotide octreotide SR 30 mg intra muscularly every 4 weeks
- Primary Outcome Measures
Name Time Method FVC changes 12 months
- Secondary Outcome Measures
Name Time Method DLCO changes 12 months